EOC
MCID: OVR094
MIFTS: 38

Ovarian Epithelial Cancer (EOC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Ovarian Epithelial Cancer

MalaCards integrated aliases for Ovarian Epithelial Cancer:

Name: Ovarian Epithelial Cancer 52 29 6
Epithelial Ovarian Cancer 52 71
Ovarian Epithelial Carcinoma 52
Ovarian Cancer, Epithelial 52
Eoc 52

Classifications:



External Ids:

UMLS 71 C0677886

Summaries for Ovarian Epithelial Cancer

MalaCards based summary : Ovarian Epithelial Cancer, also known as epithelial ovarian cancer, is related to ovarian cancer and malignant epithelial tumor of ovary. An important gene associated with Ovarian Epithelial Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha). The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include ovary, t cells and breast.

Related Diseases for Ovarian Epithelial Cancer

Diseases related to Ovarian Epithelial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 299, show less)
# Related Disease Score Top Affiliating Genes
1 ovarian cancer 28.2 PIK3CA ERLNC1 DNM3OS CERNA2 CCAT2 CCAT1
2 malignant epithelial tumor of ovary 11.8
3 primary peritoneal carcinoma 11.6
4 ovarian clear cell carcinoma 11.6
5 ovary transitional cell carcinoma 11.3
6 alopecia 10.5
7 fallopian tube carcinoma 10.5
8 neuropathy 10.5
9 peripheral nervous system disease 10.5
10 thrombocytosis 10.5
11 thrombocytopenia 10.5
12 clear cell adenocarcinoma 10.4
13 ovarian disease 10.4
14 mucinous adenocarcinoma 10.4
15 mucinous cystadenocarcinoma 10.4
16 appendix adenocarcinoma 10.4
17 ileus 10.4
18 infertility 10.3
19 severe combined immunodeficiency 10.3
20 47,xyy 10.3
21 insulin-like growth factor i 10.3
22 body mass index quantitative trait locus 1 10.3
23 cytokine deficiency 10.3
24 ovarian serous carcinoma 10.3
25 sensory peripheral neuropathy 10.3
26 lynch syndrome 10.3
27 stomatitis 10.3
28 granulocytopenia 10.3
29 familial ovarian cancer 10.3
30 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
31 pelvic inflammatory disease 10.2
32 endometriosis of ovary 10.2
33 constipation 10.2
34 ovarian cystadenoma 10.2
35 b-cell lymphoma 10.2
36 acute sensory ataxic neuropathy 10.2
37 colorectal cancer 10.2
38 body mass index quantitative trait locus 11 10.2
39 epileptic encephalopathy, childhood-onset 10.2
40 diarrhea 10.2
41 adenoma 10.2
42 48,xyyy 10.2
43 breast cancer 10.2
44 retinoblastoma 10.2
45 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.2
46 body mass index quantitative trait locus 9 10.2
47 body mass index quantitative trait locus 8 10.2
48 body mass index quantitative trait locus 4 10.2
49 body mass index quantitative trait locus 10 10.2
50 body mass index quantitative trait locus 7 10.2
51 body mass index quantitative trait locus 12 10.2
52 body mass index quantitative trait locus 14 10.2
53 body mass index quantitative trait locus 18 10.2
54 body mass index quantitative trait locus 19 10.2
55 body mass index quantitative trait locus 20 10.2
56 exanthem 10.2
57 carcinosarcoma 10.2
58 familial retinoblastoma 10.2
59 hereditary breast ovarian cancer syndrome 10.2
60 helix syndrome 10.1
61 mucositis 10.1
62 hypothyroidism 10.1
63 thyroid gland disease 10.1
64 hypoxia 10.1
65 esophageal cancer 10.1
66 wilms tumor 5 10.1
67 leukemia, acute myeloid 10.1
68 pain agnosia 10.1
69 chlamydia 10.1
70 leiomyoma 10.1
71 intestinal obstruction 10.1
72 herpes simplex 10.1
73 pulmonary embolism 10.1
74 lymph node disease 10.1
75 clear cell adenocarcinoma of the ovary 10.1
76 dysgerminoma 10.1
77 wiskott-aldrich syndrome 10.1
78 retinitis pigmentosa 11 10.1
79 branchiootic syndrome 1 10.1
80 cervical cancer 10.1
81 breast-ovarian cancer, familial 2 10.1
82 lung cancer susceptibility 3 10.1
83 polycystic ovary syndrome 10.1
84 allergic hypersensitivity disease 10.1
85 intestinal perforation 10.1
86 splenic disease 10.1
87 ovarian brenner tumor 10.1
88 benign mesothelioma 10.1
89 glioblastoma multiforme 10.1
90 papillary adenocarcinoma 10.1
91 serous cystadenocarcinoma 10.1
92 myofibroma 10.1
93 pik3ca-related overgrowth syndrome 10.1
94 bladder cancer 10.0
95 triiodothyronine receptor auxiliary protein 10.0
96 enterocolitis 10.0
97 microcephaly 1, primary, autosomal recessive 10.0
98 proteasome-associated autoinflammatory syndrome 1 10.0
99 breast-ovarian cancer, familial 1 10.0
100 anxiety 10.0
101 deficiency anemia 10.0
102 sexual disorder 10.0
103 mumps 10.0
104 pre-eclampsia 10.0
105 rickets 10.0
106 microcephaly 10.0
107 hyperandrogenism 10.0
108 hemosiderosis 10.0
109 pneumothorax 10.0
110 peritoneum cancer 10.0
111 endodermal sinus tumor 10.0
112 malignant ovarian cyst 10.0
113 papilloma 10.0
114 cystadenoma 10.0
115 endometrial adenocarcinoma 10.0
116 acute kidney failure 10.0
117 vaccinia 10.0
118 skin carcinoma 10.0
119 ovarian cystadenocarcinoma 10.0
120 malignant ovarian brenner tumor 10.0
121 hypokalemia 10.0
122 ovarian cyst 10.0
123 testicular yolk sac tumor 10.0
124 ovarian serous cystadenocarcinoma 10.0
125 lymphopenia 10.0
126 malignant pleural mesothelioma 10.0
127 krukenberg carcinoma 10.0
128 germ cells tumors 10.0
129 primary peritoneal tumor 10.0
130 inflammatory myopathy with abundant macrophages 10.0
131 rare hereditary hemochromatosis 10.0
132 malignancy diagnosed during pregnancy 10.0
133 polyploidy 10.0
134 small cell cancer of the lung 9.9 PIK3CA CCAT2
135 hyperparathyroidism 9.8
136 adenofibroma 9.8
137 malignant teratoma 9.8
138 immature teratoma of ovary 9.8
139 autoimmune oophoritis 9.8
140 rapidly involuting congenital hemangioma 9.8
141 neurofibromatosis, type ii 9.8
142 gastroesophageal reflux 9.8
143 progressive familial heart block, type ia 9.8
144 burkitt lymphoma 9.8
145 carcinoid tumors, intestinal 9.8
146 optic atrophy with or without deafness, ophthalmoplegia, myopathy, ataxia, and neuropathy 9.8
147 renal cell carcinoma, nonpapillary 9.8
148 kaposi sarcoma 9.8
149 leiomyoma, uterine 9.8
150 mesothelioma, malignant 9.8
151 migraine with or without aura 1 9.8
152 nondisjunction 9.8
153 teratoma, ovarian 9.8
154 polycystic liver disease 1 with or without kidney cysts 9.8
155 polykaryocytosis inducer 9.8
156 prostate cancer 9.8
157 schizophrenia 9.8
158 thrombophilia due to thrombin defect 9.8
159 down syndrome 9.8
160 suppressor of tumorigenicity 3 9.8
161 von hippel-lindau syndrome 9.8
162 wilms tumor 1 9.8
163 wolff-parkinson-white syndrome 9.8
164 anemia, hypochromic microcytic, with iron overload 1 9.8
165 ataxia-telangiectasia 9.8
166 coloboma, ocular, autosomal recessive 9.8
167 fanconi anemia, complementation group a 9.8
168 hemochromatosis, type 1 9.8
169 lymphoma, hodgkin, classic 9.8
170 immune deficiency disease 9.8
171 laryngoonychocutaneous syndrome 9.8
172 multiple pterygium syndrome, lethal type 9.8
173 ocular motor apraxia 9.8
174 osteogenic sarcoma 9.8
175 polycystic kidney disease 4 with or without polycystic liver disease 9.8
176 smith-lemli-opitz syndrome 9.8
177 thymoma, familial 9.8
178 xeroderma pigmentosum, variant type 9.8
179 sarcoma, synovial 9.8
180 ataxia and polyneuropathy, adult-onset 9.8
181 aging 9.8
182 gallbladder disease 1 9.8
183 fanconi anemia, complementation group f 9.8
184 lymphoma, non-hodgkin, familial 9.8
185 meningioma, radiation-induced 9.8
186 nasopharyngeal carcinoma 9.8
187 meningioma, familial 9.8
188 coronary heart disease 1 9.8
189 ovarian cancer 1 9.8
190 endometrial cancer 9.8
191 human immunodeficiency virus type 1 9.8
192 colorectal cancer 11 9.8
193 gastric cancer 9.8
194 myelodysplastic syndrome 9.8
195 estrogen resistance 9.8
196 leukemia, acute lymphoblastic 3 9.8
197 thrombocytopenia 6 9.8
198 angina pectoris 9.8
199 pulmonary hypertension 9.8
200 hypochromic microcytic anemia 9.8
201 diffuse large b-cell lymphoma 9.8
202 limb ischemia 9.8
203 oral squamous cell carcinoma 9.8
204 ectopic pregnancy 9.8
205 thrombosis 9.8
206 autosomal dominant non-syndromic intellectual disability 1 9.8
207 hereditary lymphedema i 9.8
208 primary microcephaly 9.8
209 bacterial infectious disease 9.8
210 glucose intolerance 9.8
211 lactose intolerance 9.8
212 short bowel syndrome 9.8
213 hydronephrosis 9.8
214 pertussis 9.8
215 spinal meningioma 9.8
216 endosalpingiosis 9.8
217 pica disease 9.8
218 neutropenia 9.8
219 pancytopenia 9.8
220 acute leukemia 9.8
221 telangiectasis 9.8
222 polyneuropathy 9.8
223 squamous cell papilloma 9.8
224 toxic shock syndrome 9.8
225 pleural disease 9.8
226 urticaria 9.8
227 mental depression 9.8
228 cystitis 9.8
229 duodenal ulcer 9.8
230 squamous cell carcinoma 9.8
231 vascular disease 9.8
232 peritoneal mesothelioma 9.8
233 melanoma 9.8
234 adenosarcoma 9.8
235 rectum cancer 9.8
236 keratopathy 9.8
237 kidney cancer 9.8
238 papillary serous adenocarcinoma 9.8
239 transitional cell carcinoma 9.8
240 myoma 9.8
241 tic disorder 9.8
242 endometriosis 9.8
243 cervix carcinoma 9.8
244 adenocarcinoma 9.8
245 female reproductive endometrioid cancer 9.8
246 cystadenocarcinoma 9.8
247 papillary carcinoma 9.8
248 thymoma 9.8
249 teratocarcinoma 9.8
250 teratoma 9.8
251 embryonal carcinoma 9.8
252 cellulitis 9.8
253 ovarian mucinous cystadenocarcinoma 9.8
254 ovarian mucinous adenocarcinoma 9.8
255 fallopian tube adenocarcinoma 9.8
256 ovary adenocarcinoma 9.8
257 gastric adenocarcinoma 9.8
258 pseudohermaphroditism 9.8
259 vaginal discharge 9.8
260 anovulation 9.8
261 pancreatic adenocarcinoma 9.8
262 hyperglycemia 9.8
263 secretory meningioma 9.8
264 lymphoplasmacyte-rich meningioma 9.8
265 liver cirrhosis 9.8
266 ovarian clear cell adenocarcinoma 9.8
267 ovarian endodermal sinus tumor 9.8
268 clear cell adenofibroma 9.8
269 cystadenofibroma 9.8
270 ovarian germ cell teratoma 9.8
271 kidney disease 9.8
272 fallopian tube serous adenocarcinoma 9.8
273 endometrioid ovary carcinoma 9.8
274 mucinous cystadenofibroma 9.8
275 radiation cystitis 9.8
276 hyperthyroidism 9.8
277 periodontitis 9.8
278 peritonitis 9.8
279 appendicitis 9.8
280 myeloid leukemia 9.8
281 diabetes mellitus 9.8
282 irritable bowel syndrome 9.8
283 mast cell activation syndrome 9.8
284 refsum disease with increased pipecolic acidemia 9.8
285 encephalopathy 9.8
286 headache 9.8
287 paraneoplastic syndromes 9.8
288 syncope 9.8
289 malignant peritoneal mesothelioma 9.8
290 cerebrofacial arteriovenous metameric syndrome 9.8
291 mucinous adenocarcinoma of ovary 9.8
292 rare tumor 9.8
293 rare gynecological tumor 9.8
294 cardiogenic shock 9.8
295 thyroid carcinoma 9.8
296 glioma 9.7 PIK3CA CCAT2 CCAT1
297 malignant glioma 9.7 CCAT1 ADAMTS9-AS1
298 lung squamous cell carcinoma 9.6 PIK3CA CCAT2 CCAT1
299 intrahepatic cholangiocarcinoma 9.6 CPS1-IT1 CCAT2 CCAT1

Graphical network of the top 20 diseases related to Ovarian Epithelial Cancer:



Diseases related to Ovarian Epithelial Cancer

Symptoms & Phenotypes for Ovarian Epithelial Cancer

Drugs & Therapeutics for Ovarian Epithelial Cancer

Drugs for Ovarian Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 393, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
3
Olaparib Approved Phase 4 763113-22-0 23725625
4
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
5 Gastrointestinal Agents Phase 4
6 Poly(ADP-ribose) Polymerase Inhibitors Phase 4
7 Antirheumatic Agents Phase 4
8 Analgesics Phase 4
9 Analgesics, Non-Narcotic Phase 4
10 Cyclooxygenase Inhibitors Phase 4
11 Anti-Inflammatory Agents Phase 4
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4
13 Platelet Aggregation Inhibitors Phase 4
14 Antipyretics Phase 4
15
Melphalan Approved Phase 3 148-82-3 460612 4053
16
Sodium citrate Approved, Investigational Phase 3 68-04-2
17
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
18
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
19
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
20
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
22
Ondansetron Approved Phase 3 99614-02-5 4595
23
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
24
Captopril Approved Phase 3 62571-86-2 44093
25
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
26
Ribavirin Approved Phase 3 36791-04-5 37542
27
Palivizumab Approved, Investigational Phase 3 188039-54-5
28
Acyclovir Approved Phase 3 59277-89-3 2022
29
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
30
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
31
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
32
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
33
Bevacizumab Approved, Investigational Phase 3 216974-75-3
34
Gemcitabine Approved Phase 3 95058-81-4 60750
35
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
36
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
37
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
38
Adenosine Approved, Investigational Phase 3 58-61-7 60961
39
Talazoparib Approved, Investigational Phase 3 1207456-01-6 135565082
40
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
41
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
42
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
43
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
44
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
45
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
46
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
47
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
48
Polyestradiol phosphate Approved Phase 3 28014-46-2
49
Mycophenolic acid Approved Phase 3 24280-93-1 446541
50
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
51
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
52
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
53 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
54 Molgramostim Investigational Phase 3 99283-10-0
55
Trebananib Investigational Phase 3 894356-79-7
56 Anti-Bacterial Agents Phase 3
57 Alkylating Agents Phase 3
58 Citrate Phase 3
59
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
60 Cytochrome P-450 Enzyme Inhibitors Phase 3
61
Hydroxyitraconazole Phase 3
62 Antifungal Agents Phase 3
63 Antiparasitic Agents Phase 3
64 Antiprotozoal Agents Phase 3
65 Cytochrome P-450 CYP3A Inhibitors Phase 3
66 Liver Extracts Phase 3
67 Cola Phase 3
68 Epothilones Phase 3
69 Epothilone B Phase 3
70 Narcotics Phase 3
71 Anesthetics, General Phase 3
72 Analgesics, Opioid Phase 3
73 Anesthetics, Intravenous Phase 3
74 Antiemetics Phase 3
75 glucocorticoids Phase 3
76 Antihypertensive Agents Phase 3
77 Neurotransmitter Agents Phase 3
78 Anti-Anxiety Agents Phase 3
79 Psychotropic Drugs Phase 3
80 Dermatologic Agents Phase 3
81 Antipsychotic Agents Phase 3
82
protease inhibitors Phase 3
83 HIV Protease Inhibitors Phase 3
84 Angiotensin-Converting Enzyme Inhibitors Phase 3
85 valacyclovir Phase 3
86 Amebicides Phase 3
87 Liposomal amphotericin B Phase 3
88 DHEA (Dehydroepiandrosterone) Phase 3
89 Vitamin B 6 Phase 3
90 Maytansine Phase 3
91 Sunflower Phase 3
92 Angiogenesis Inhibitors Phase 3
93 Antimetabolites Phase 3
94 Antibodies, Monoclonal Phase 3
95 Immunoglobulins, Intravenous Phase 3
96 Mitogens Phase 3
97 Endothelial Growth Factors Phase 3
98 Immunoglobulin G Phase 3
99 Anesthetics Phase 3
100 Anesthetics, Local Phase 3
101 Aromatase Inhibitors Phase 3
102 Immunosuppressive Agents Phase 3
103 Antibiotics, Antitubercular Phase 3
104 topoisomerase I inhibitors Phase 3
105
Liposomal doxorubicin Phase 3 31703
106 Hematinics Phase 3
107 Contraceptive Agents Phase 3
108 Contraceptives, Oral Phase 3
109 Epoetin alfa Phase 3 113427-24-0
110 Abagovomab Phase 2, Phase 3
111 Estradiol 17 beta-cypionate Phase 3
112 Contraceptives, Oral, Combined Phase 3
113 Estradiol 3-benzoate Phase 3
114 Norgestimate, ethinyl estradiol drug combination Phase 3
115 Antitubercular Agents Phase 3
116
Pyridoxal Experimental, Nutraceutical Phase 3 66-72-8 1050
117
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
118
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
119
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
120
Dipyridamole Approved Phase 2 58-32-2 3108
121
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
122
Indinavir Approved Phase 2 150378-17-9 5362440
123
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
124
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
125
Thiotepa Approved, Investigational Phase 1, Phase 2 52-24-4 5453
126
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
127
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 11431660 5330286
128
Lapatinib Approved, Investigational Phase 1, Phase 2 231277-92-2, 388082-78-8 208908 9941095
129
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
130
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
131
Floxuridine Approved Phase 2 50-91-9 5790
132
Carmustine Approved, Investigational Phase 2 154-93-8 2578
133
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
134
Ifosfamide Approved Phase 2 3778-73-2 3690
135
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
136
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
137
Tocopherol Approved, Investigational Phase 2 1406-66-2, 54-28-4 14986
138
Fondaparinux Approved, Investigational Phase 2 104993-28-4
139
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
140
Nintedanib Approved Phase 2 656247-17-5 56843413
141
Pegaspargase Approved, Investigational Phase 2 130167-69-0
142
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
143
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
144
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
145
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
146
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
147 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
148
alemtuzumab Approved, Investigational Phase 2 216503-57-0
149
Oprelvekin Approved, Investigational Phase 2 145941-26-0
150
Bicalutamide Approved Phase 2 90357-06-5 2375 56069
151
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
152
Belinostat Approved, Investigational Phase 2 866323-14-0
153
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
154
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
155
Salicylic acid Approved, Investigational, Vet_approved Phase 2 69-72-7 338